Immunosuppressive mechanisms in glioblastoma
EK Nduom, M Weller, AB Heimberger - Neuro-oncology, 2015 - academic.oup.com
Despite maximal surgical and medical therapy, the treatment of glioblastoma remains a
seriously vexing problem, with median survival well under 2 years and few long-term …
seriously vexing problem, with median survival well under 2 years and few long-term …
Analysis of the intricate relationship between chronic inflammation and cancer
EZP Chai, KS Siveen, MK Shanmugam… - Biochemical …, 2015 - portlandpress.com
Deregulated inflammatory response plays a pivotal role in the initiation, development and
progression of tumours. Potential molecular mechanism (s) that drive the establishment of …
progression of tumours. Potential molecular mechanism (s) that drive the establishment of …
Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma
Severe and prolonged lymphopenia frequently occurs in patients with glioblastoma after
standard chemoradiotherapy and has been associated with worse survival, but its …
standard chemoradiotherapy and has been associated with worse survival, but its …
Immune escape in glioblastoma multiforme and the adaptation of immunotherapies for treatment
JRD Pearson, S Cuzzubbo, S McArthur… - Frontiers in …, 2020 - frontiersin.org
Glioblastoma multiforme (GBM) is the most frequently occurring primary brain tumor and has
a very poor prognosis, with only around 5% of patients surviving for a period of 5 years or …
a very poor prognosis, with only around 5% of patients surviving for a period of 5 years or …
A cancer research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma
R Rampling, S Peoples, PJ Mulholland, A James… - Clinical cancer …, 2016 - AACR
Purpose: To perform a two-cohort, phase I safety and immunogenicity study of IMA950 in
addition to standard chemoradiotherapy and adjuvant temozolomide in patients with newly …
addition to standard chemoradiotherapy and adjuvant temozolomide in patients with newly …
[HTML][HTML] Enhanced antitumor efficacy of biocompatible magnetosomes for the magnetic hyperthermia treatment of glioblastoma
R Le Fèvre, M Durand-Dubief, I Chebbi… - Theranostics, 2017 - ncbi.nlm.nih.gov
In this study, biologically synthesized iron oxide nanoparticles, called magnetosomes, are
made fully biocompatible by removing potentially toxic organic bacterial residues such as …
made fully biocompatible by removing potentially toxic organic bacterial residues such as …
Immune infiltration of tumor microenvironment following immunotherapy for glioblastoma multiforme
G Sokratous, S Polyzoidis, K Ashkan - Human vaccines & …, 2017 - Taylor & Francis
Autologous dentritic cell immunotherapy has been proven effective in treating tumors
outside the central nervous system. Current evidence from phase I and II trials suggest a …
outside the central nervous system. Current evidence from phase I and II trials suggest a …
Modeling glioblastoma complexity with organoids for personalized treatments
KD Pawlowski, JT Duffy, MV Babak… - Trends in molecular …, 2023 - cell.com
Glioblastoma (GBM) remains a fatal diagnosis despite the current standard of care of
maximal surgical resection, radiation, and temozolomide (TMZ) therapy. One aspect that …
maximal surgical resection, radiation, and temozolomide (TMZ) therapy. One aspect that …
Recent progress in the synergistic combination of nanoparticle‐mediated hyperthermia and immunotherapy for treatment of cancer
ZR Stephen, M Zhang - Advanced healthcare materials, 2021 - Wiley Online Library
Immunotherapy has demonstrated great clinical success in certain cancers, driven primarily
by immune checkpoint blockade and adoptive cell therapies. Immunotherapy can elicit …
by immune checkpoint blockade and adoptive cell therapies. Immunotherapy can elicit …